Method and device for quality controlling a blood-based product

1. A method for quality controlling a blood-based product, wherein the method comprises:

providing a computer comprising one or a plurality of processors or controllers;

storing, in a database in a memory of the computer, a plurality of reference spectra, wherein the stored plurality of reference spectra includes one or more of:

a position of Raman peaks and/or wavenumber ranges of fresh cells of different cell types of blood based products, wherein the blood-based products comprise one or more of an erythrocyte concentrate, a thrombocyte concentrate, a granulocyte concentrate, a leukocyte concentrate, whole blood and blood plasma;

a position of Raman peaks and/or wavenumber ranges of functionally modified cells of the different cell types of the blood based products and

information regarding ranges of multi-dimensional spaces of a cluster analysis, in which the reference spectra are respectively arranged;

collecting, in an optical trap, at least one cell of a sample of a liquid blood-based product from one of the plurality of blood donors

recording a Raman spectrum of the at least one cell of the sample by means of Raman spectroscopy;

comparing the recorded Raman spectrum of the at least one cell of the sample with the plurality of reference spectra stored in the database;

evaluating one or more of cell age, cell death, sterility, levels of impurity and cell functionality of the at least one cell of the sample based on results of the comparison; and

determining whether the liquid blood-based product donated by the one of the plurality of blood donors is usable for a transfusion based on results of the evaluation.

2. The method according to claim 1 ,

wherein the evaluating includes identifying a functional modification of the at least one cell of the sample.

3. The method according to claim 2 ,

wherein the evaluating further comprises quantitatively determining which proportion of the at least one cell of the sample is subject to a functional modification.

4. The method according to claim 3 ,

wherein the quantitatively determining of which proportion of the at least one cell of the sample is subject to the functional modification further comprises respectively subjecting a plurality of recorded Raman spectra to a principal component analysis.

5. The method according to claim 1 ,

wherein the evaluating further comprises identifying the presence of bacteria or other impurities in the sample of the blood-based product.

6. The method according to claim 1 ,

wherein the evaluation comprises a spectral analysis of the Raman spectrum.

7. The method according to claim 1 ,

wherein the optical trap is produced by an excitation beam of a Raman spectroscopy system.

8. The method according to claim 1 , comprising

wherein the at least one cell of the sample of the liquid blood-based product is selected from a group consisting of erythrocytes, thrombocytes, granulocytes and leukocytes.

9. The method according to claim 1 , further comprising:

declaring the blood-based that has been tested by subjecting the sample to Raman spectroscopy usable; and

transfusing a patient with the blood-based product.

10. The method according to claim 1 , wherein:

the collecting of the at least one cell of the sample of the liquid blood-based product includes collecting a plurality of cell types; and

the evaluating includes identifying a functional modification of different categories of cells of the plurality of cell types.

11. The method according to claim 10 , further comprising:

recording several internal functional modifications of the different categories of cells.